Erythrocyte cAMP in Determining Frequency of Acute Pain Episodes in Sickle Cell Disease Patients from Odisha State, India
暂无分享,去创建一个
P. Das | A. Pradhan | R. K. Behera | Shalini Sinha | J. Mohanty | P. Mohanty | B. P. Jit | P. Purohit | Siris Patel | S. Meher | K. Das
[1] P. Das,et al. Association of fetal hemoglobin level with frequency of acute pain episodes in sickle cell disease (HbS-only phenotype) patients. , 2019, Blood cells, molecules & diseases.
[2] M. Gladwin,et al. Pathophysiology of Sickle Cell Disease. , 2019, Annual review of pathology.
[3] M. Steinberg,et al. Fetal hemoglobin in sickle cell anemia: The Arab‐Indian haplotype and new therapeutic agents , 2017, American journal of hematology.
[4] Hillel W. Cohen,et al. Elevated Steady State WBC and Platelet Counts Are Associated with Frequent Emergency Room Use in Adults with Sickle Cell Anemia , 2015, PloS one.
[5] G. Lykotrafitis,et al. AKAP-dependent modulation of BCAM/Lu adhesion on normal and sickle cell disease RBCs revealed by force nanoscopy. , 2014, Biophysical journal.
[6] P. Purohit,et al. Prevalence of Deletional Alpha Thalassemia and Sickle Gene in a Tribal Dominated Malaria Endemic Area of Eastern India , 2014, ISRN hematology.
[7] J. Elion,et al. Hydroxycarbamide Decreases Sickle Reticulocyte Adhesion to Resting Endothelium by Inhibiting Endothelial Lutheran/Basal Cell Adhesion Molecule (Lu/BCAM) through Phosphodiesterase 4A Activation* , 2014, The Journal of Biological Chemistry.
[8] O. Oshinaike,et al. Haematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria , 2012, BMC Research Notes.
[9] Mike A Laffan Dm Frcp FRCPath,et al. Dacie and Lewis Practical Haematology , 2012 .
[10] R. Lefkowitz,et al. Therapeutic potential of β-arrestin- and G protein-biased agonists. , 2011, Trends in molecular medicine.
[11] J. Elion,et al. [Pathophysiology of sickle cell disease]. , 2010, Medecine tropicale : revue du Corps de sante colonial.
[12] D. Bachir,et al. Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation. , 2010, Blood.
[13] Keshava Rajagopal,et al. Teaching old receptors new tricks: biasing seven-transmembrane receptors , 2010, Nature Reviews Drug Discovery.
[14] ��� S������i. gene analysis. , 2010 .
[15] D. Kaul,et al. Sickle Red Cell–Endothelium Interactions , 2009, Microcirculation.
[16] A. Ashley-Koch,et al. β2‐Adrenergic receptor and adenylate cyclase gene polymorphisms affect sickle red cell adhesion , 2008, British journal of haematology.
[17] J. Elion,et al. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea. , 2008, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.
[18] M. Dewhirst,et al. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. , 2007, Blood.
[19] M. Telen. Role of adhesion molecules and vascular endothelium in the pathogenesis of sickle cell disease. , 2007, Hematology. American Society of Hematology. Education Program.
[20] M. Steinberg. Predicting clinical severity in sickle cell anaemia , 2005, British journal of haematology.
[21] M. Telen,et al. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-αvβ3 interactions , 2004 .
[22] K. Ataga,et al. Mechanism of CD47-induced α4β1 Integrin Activation and Adhesion in Sickle Reticulocytes* , 2004, Journal of Biological Chemistry.
[23] M. Telen,et al. Epinephrine acts through erythroid signaling pathways to activate sickle cell adhesion to endothelium via LW-alphavbeta3 interactions. , 2004, Blood.
[24] M. Telen,et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM/Lu-dependent sickle (SS) RBC adhesion. , 2003, Blood.
[25] J. Benovic. Novel β2-adrenergic receptor signaling pathways , 2002 .
[26] D. Mohanty,et al. Sickle cell disease in India. , 1958, Blood.
[27] L. Parise,et al. Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. , 2001, The Journal of clinical investigation.
[28] D. Higgs,et al. Single-tube multiplex-PCR screen for common deletional determinants of α-thalassemia , 2000 .
[29] S Levin,et al. β‐Adrenergic agonists regulate cell membrane fluctuations of human erythrocytes , 1999, The Journal of physiology.
[30] M. Steinberg. 6 Pathophysiology of sickle cell disease , 1998 .
[31] O. Platt,et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.
[32] E Vichinsky,et al. Pain in sickle cell disease. Rates and risk factors. , 1991, The New England journal of medicine.
[33] M. Caron,et al. beta-Adrenergic receptor kinase. Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. , 1988, The Journal of biological chemistry.
[34] J. Hofrichter,et al. Hemoglobin S gelation and sickle cell disease. , 1987, Blood.
[35] S. Orkin,et al. Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. , 1987, The New England journal of medicine.
[36] A. Gilman,et al. G proteins: transducers of receptor-generated signals. , 1987, Annual review of biochemistry.
[37] H. Bunn,et al. Hemoglobin: Molecular, Genetic and Clinical Aspects , 1984 .